Bone drug shows promise for rare mast cell disorder

NCT ID NCT03401060

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether denosumab, a drug given as a shot every 6 months, can improve bone density in people with osteoporosis caused by systemic mastocytosis. 24 adults with the condition took part. The goal was to see if the drug strengthens bones and prevents fractures better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Mastocytosis, Systemic osteoporosis systemic mastocytosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS SYSTEMIC MASTOCYTOSIS

Contacts and locations

Locations

Caen Hospital, Clinical haematology department

Caen, 14033, France
Cochin Hospital, Rheumatology department

Paris, 75014, France
Estaing Hospital, Cellular therapy and clinical haematology department

Clermont-Ferrand, 63100, France
Jean Minjoz Hospital, Dermatology department

Besançon, 25030, France
La Pitié-Salpêtrière Hospital, Internal medicine and clinical immunology department

Paris, 75013, France
La Timone Hospital, Dermatology and cutaneous oncology department

Marseille, 13385, France
Lapeyronie Hospital, Rheumatology and Immunology department

Montpellier, 34295, France
Lille CHRU Hospital, Internal medicine and clinical immunology department

Lille, 59037, France
Necker Hospital, Adult haematology department

Paris, 75015, France
Strasbourg Hospital, Rheumatology department

Strasbourg, 67098, France
Toulouse Hospital, Dermatology department

Toulouse, 31060, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.